07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

CoAprovel irbesartan/hydrochlorothiazide regulatory update

EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include a contraindication for patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2)...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Aprovel irbesartan regulatory update

EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include a contraindication for patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2)...
08:00 , Jan 28, 2013 |  BioCentury  |  Finance

Oleg's asymmetry

Longtime BVF Partners portfolio manager Oleg Nodelman is betting there's room for a new fund focused on what he calls "asymmetric opportunities." Last October, Nodelman left the hedge fund after about 11 years to launch EcoR1...
07:00 , Oct 29, 2012 |  BioCentury  |  Finance

NextWave's option arithmetic

NextWave Pharmaceuticals Inc.'s investors are in line for at least a 2.5X return on the $105 million they have put into the CNS company after Pfizer Inc. (NYSE:PFE) exercised an option to acquire it last...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Bristol-Myers, Sanofi deal

Sanofi and Bristol-Myers restructured a 1993 co-promotion deal for three cardiovascular drugs - Plavix clopidogrel, Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide - following the drugs' loss of exclusivity in the U.S. this year....
00:59 , Oct 4, 2012 |  BC Extra  |  Company News

Bristol-Myers, Sanofi amend cardiovascular partnership

Sanofi (Euronext:SAN; NYSE:SNY) and Bristol-Myers Squibb Co. (NYSE:BMY) restructured a co-promotion deal for three cardiovascular drugs -- Plavix clopidogrel, Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide -- following the drugs' loss of exclusivity in the U.S. this...
07:00 , Jul 30, 2012 |  BioCentury  |  Finance

HGS in hindsight

Human Genome Sciences Inc. (NASDAQ:HGSI) refused a takeout offer two years ago for more than twice the $2.9 billion partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will pay for the biotech. Although HGS hasn't disclosed who made...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Teva sales and marketing update

Teva launched generic versions of cardiovascular drugs Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) in the U.S. The pharmas...
07:00 , Oct 24, 2011 |  BioCentury  |  Finance

Abbott's bit parts

Abbott Laboratories is the latest pharma to hope that splitting up will unlock value. But last week's news that Abbott plans to become two companies - a diversified medical products company and a research-based pharmaceutical...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because VCs...